X hits on this document





1 / 18


Glenn R. Cunningham, MD Professor of Medicine and Molecular

& Cellular Biology Baylor College of Medicine Medical Director, St. Luke’s Episcopal Hospital-

Baylor College of Medicine Diabetes Program Houston, Texas

Ridwan Shabsigh, MD Director, Division of Urology Maimonides Medical Center Brooklyn, New York Professor of Urology College of Physicians & Surgeons of Columbia University New York, New York


André T. Gua , MD Director, Center for Sexual Function Lahey Clinic Northshore Peabody, Massachusetts Clinical Assistant Professor of Medicine

(Endocrinology) Harvard Medical School Boston, Massachusetts

Ajay Nehra, MD Professor of Urology Department of Urology Mayo Clinic College of Medicine Rochester, Minnesota

Robert S. Tan, MD Director, OPAL Medical Clinic Associate Professor of Medicine (Geriatrics) Baylor College of Medicine Clinical Associate Professor of Family Medicine University of Texas Houston, Texas

Martin M. Miner, MD Director, Men’s Health Center Miriam Hospital Clinical Associate Professor of Family Medicine Alpert Medical School Brown University Providence, Rhode Island

Richard Sadovsk , MD Associate Professor of Family Medicine State University of New York

Health Science Center at Brooklyn Brooklyn, New York

Dear Colleague:

Recognizing the importance of awareness and education regarding hypogonadism—a highly prevalent and often undertreated condition in the Unites States—experts from the fields of endocrinology, primary care, and urology participated in a roundtable discussion focusing on the recognition and treatment of hypogonadism in men. On April 26, 2008, the distinguished faculty convened in Boston to compile a comprehensive overview of hypogonadism.

One of the greatest challenges in treating hypogonadism in men is learning how to assess and diagnose this condition. Clinical guidelines are unclear, laboratory assays are uncertain, and the symptoms resulting from low testosterone levels are vague and nonspecific. A diagnosis of hypogonadism is often missed because of underlying comorbid conditions, some of which may be exacerbated by low testosterone levels.

The goal of the expert roundtable discussion was to educate clinicians about the following: the complex characteristics of hypogonadism and how it can manifest as a constellation of nonspecific signs and symptoms; the importance of identifying hypogonadism when a man presents with the symptoms of erectile dysfunction, depression, or loss of energy; laboratory testing of testosterone as a tool to assess and diagnose hypogonadism and to manage signs and symptoms; realistic treatment goals based on clinical presentation and laboratory parameters; the options available to treat hypogonadism; and when it is appropriate to refer to specialists.

This publication contains the proceedings from the multidisciplinary panel discussion, a review of the current data on hypogonadism, and recommendations that may be incorporated into your clinical practice. For additional educational activities on hypogonadism, including a downloadable Esource slide library, please visit http://www.TestosteroneUpdate.org.


Glenn R. Cunningham, MD Co-Chairperson

Ridwan Shabsigh, MD Co-Chairperson

Jointly sponsored by





This activity is supported by an independent educational grant provided by

Document info
Document views69
Page views69
Page last viewedSun Jan 22 17:36:44 UTC 2017